Advertisement

Oxford Biomedica bags Novartis leukaemia deal

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

The deal, which is worth between £2.5m and £4.0m to Oxford Biomedica over the next 12 months, will see the Oxford company's LentiVector gene delivery technology manufacture clinical grade genetic material for Novartis's CTL019 clinical development programme.

Advertisement - Article continues below

CTL019 is the lead project in a leukaemia-focused collaboration between the Swiss 'big pharma' player and the University of Pennsylvania.

CTL019 uses a gene delivery system called a lentiviral vector to genetically modify a patient's immune cells before they are re-infused into patients.

According to Edison Investment Research, such 'ex vivo' techniques "are typically difficult to scale-up easily and the deal helps validate Oxford BioMedica's viral vector production expertise".

"Additionally, it also highlights that gene therapy has the potential to dramatically alter life-threatening and severely debilitating disease outcomes."

Oxford BioMedica's Chief Executive Officer John Dawson said: "The strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business and this collaboration is an example of how we can commercialise our expertise."

Edison notes that the Novartis payments should mean that the company, which had net cash at end-2012 of £14.1m and is estimated to be burning cash at around £1.0m per month, has enough cash to reach the second quarter of 2014.

Shares in Oxford Biomedica were up 15% at 1.9p by 09:49 on the morning of the announcement.

OH

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

An economics lesson from my barber
Inflation

An economics lesson from my barber

On reopening his shop after lockdown, Dominic Frisby’s barber doubled his prices. It’s all part of the post-Covid inflation process – and we’re going …
8 Jul 2020
What gold, bonds and tech stocks have in common
Stockmarkets

What gold, bonds and tech stocks have in common

"Risk off" or "safe haven" assets such as gold and government bonds have been doing well lately. But so have riskier tech stocks. That seems to defy c…
10 Jul 2020
House price crash: UK property prices are falling – so where next?
Property

House price crash: UK property prices are falling – so where next?

With UK property prices falling for the first time in eight years, are we about to see a house price crash? John Stepek looks at what’s behind the sli…
2 Jul 2020